

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism

Valeria Cagno^{1,2,3†}, Patrizia Andreozzi^{4,5†}, Marco D'Alicarnasso⁶, Paulo Jacob Silva², Marie Mueller², Marie Galloux⁷, Ronan Le Goffic⁷, Samuel T. Jones^{2,8}, Marta Vallino⁹, Jan Hodek¹⁰, Jan Weber¹⁰, Soumyo Sen¹¹, Emma-Rose Janeček², Ahmet Bekdemir², Barbara Sanavio¹², Chiara Martinelli⁴, Manuela Donalizio¹, Marie-Anne Rameix Welti^{13,14}, Jean-Francois Eleouet⁷, Yanxiao Han¹¹, Laurent Kaiser¹⁵, Lela Vukovic¹⁶, Caroline Tapparel^{3,15}, Petr Král^{11,17}, Silke Krol^{12,18}, David Lembo^{1*} and Francesco Stellacci^{2,19*}

Viral infections kill millions yearly. Available antiviral drugs are virus-specific and active against a limited panel of human pathogens. There are broad-spectrum substances that prevent the first step of virus-cell interaction by mimicking heparan sulfate proteoglycans (HSPG), the highly conserved target of viral attachment ligands (VALs). The reversible binding mechanism prevents their use as a drug, because, upon dilution, the inhibition is lost. Known VALs are made of closely packed repeating units, but the aforementioned substances are able to bind only a few of them. We designed antiviral nanoparticles with long and flexible linkers mimicking HSPG, allowing for effective viral association with a binding that we simulate to be strong and multivalent to the VAL repeating units, generating forces (~190 pN) that eventually lead to irreversible viral deformation. Virucidal assays, electron microscopy images, and molecular dynamics simulations support the proposed mechanism. These particles show no cytotoxicity, and *in vitro* nanomolar irreversible activity against herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV), dengue and lenti virus. They are active *ex vivo* in human cervicovaginal histocultures infected by HSV-2 and *in vivo* in mice infected with RSV.

Infectious diseases account for ~20% of global mortality, and viruses are responsible for about one third of these deaths¹. Lower respiratory infections and human immunodeficiency virus (HIV) are among the ten most common causes of deaths worldwide, and they contribute substantially to healthcare costs². Emerging viruses (for example, Ebola) add yearly to this death toll. The best approach to prevent viral infections is vaccination; however, there exist only a limited number of vaccines, and the ones that exist are not equally available in all parts of the world³. After infection, antiviral drugs are the only treatment option, but even in this case there are only a limited number of approved antiviral drugs, and they are all virus-specific. There is a dire need for broad-spectrum antiviral drugs that can act on a large number of existing and emerging viruses.

Current therapeutics can be subdivided into small molecules (for example, nucleoside analogues and peptidomimetics), proteins able to stimulate the immune response (for example, interferon), and oligonucleotides (for example, fomivirsen)⁴. They are mainly directed against HIV, hepatitis B virus (HBV), hepatitis C

virus (HCV), herpes simplex virus (HSV), human cytomegalovirus (HCMV) and influenza virus. They act intracellularly, mostly on viral enzymes that are essential for viral replication but differ from any other host enzyme to allow for selectivity. Since viruses largely depend on the biosynthetic machinery of infected cells for their replication, the specificity of antiviral drugs is far from ideal, resulting in a general intrinsic toxicity associated with such treatment^{5,6}. Additionally, most viruses mutate rapidly due to error-prone replication machinery; therefore, they often develop resistance⁷. Finally, the use of virus-specific proteins as a target of antiviral drugs makes it difficult to develop broad-spectrum antivirals capable of acting on a large number of viruses that are phylogenetically unrelated and structurally different.

Virustatic substances act outside the cell by interfering with the first phases of the viral replication cycle. They can be broad spectrum and non-toxic. Their activity depends on a reversible binding event; the reversibility of the mechanism makes them medically irrelevant. For example, upon dilution the substance is detached

¹Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino, Orbassano, Italy. ²Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. ³Faculty of Medicine of Geneva, Department of Microbiology and Molecular medicine, Geneva, Switzerland.

⁴IFOM - FIRC Institute of Molecular Oncology, IFOM-IEO Campus, Milan, Italy. ⁵CIC biomaGUNE Soft Matter Nanotechnology Group San Sebastian-Donostia, 20014 Donostia San Sebastián, Spain. ⁶Fondazione Centro Europeo Nanomedicina (CEN), Milan, Italy. ⁷VIM, INRA, Université Paris-Saclay, Jouy-en-Josas, France. ⁸Jones Lab, School of Materials, University of Manchester, Oxford Road, Manchester M13 9PL, UK. ⁹Istituto per la Protezione Sostenibile delle Piante, CNR, Torino, Italy. ¹⁰Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic. ¹¹Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, USA. ¹²Fondazione IRCCS Istituto Neurologico "Carlo Besta", IFOM-IEO Campus, Milan, Italy. ¹³UMR INSERM U1173 I2, UFR des Sciences de la Santé Simone Veil—UVSQ, Montigny-Le-Brettonneux, France. ¹⁴AP-HP, Laboratoire de Microbiologie, Hôpital Ambroise Paré, 92104 Boulogne-Billancourt, France. ¹⁵Geneva University Hospitals, Infectious Diseases Divisions, Geneva, Switzerland. ¹⁶Department of Chemistry, University of Texas at El Paso, El Paso, Texas 79968, USA. ¹⁷Department of Physics and Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60607, USA. ¹⁸IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.

¹⁹Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. †These authors contributed equally to this work. *e-mail: david.lembo@unito.it; francesco.stellacci@epfl.ch

from an unaltered viral particle, allowing the virus to infect again. To achieve broad-spectrum efficacy, current virustatic materials (for example, heparin, polyanions) target virus–cell interactions that are common to many viruses. One of these interactions is that between the VAL and its associated cell receptor responsible for the first step of the virus replication cycle. Many viruses, including HIV-1, HSV, HCMV, HPV, RSV and flavivirus⁸, exploit HSPGs as the target of their VALs. HSPGs are expressed on the surface of almost all eukaryotic cell types. The binding between viruses and HSPGs usually occurs via the interaction of closely packed arrangements of multiple basic amino acids on the proteins, that constitute the VAL, with the negatively charged sulfated groups of heparan sulfate (HS) in the glycocalyx of the cell surface⁹. A long list of HSPG-mimicking materials such as heparin^{10,11}, sulfated polysaccharides^{9,12}, or sulfonic-acid-decorated polymers, dendrimers, and nanoparticles^{13–17} have been tested and shown to exert potent virustatic activity *in vitro*, none have shown efficacy in humans. The only three polyanionic anti-HIV-1 microbicides that reached phase III clinical trial—that is, polysulfonated PRO2000, the polysulfated Carraguard, and cellulose sulfate Ushercell—did not prevent vaginal HIV-1 transmission, and in some cases even increased the rate of infection^{18–21}. One of the possible explanations is that their effect was simply virustatic, and hence vaginal and seminal fluids lead to the dilution of both the viruses and the active compounds, which resulted in the complete loss of binding and release of active virus.

Arguably, the ideal drug against a viral infection would be virucidal. Virucidal molecules cause irreversible viral deactivation; indeed, their effect is retained even if dilution occurs after the initial interaction with the virus²². There is a vast literature on many virucidal materials, ranging from simple detergents, to strong acids, or more refined polymers²³, and nanoparticles (NPs)^{24–27} that, in some cases, are capable of releasing ions^{28,29}. In all cases, the approaches utilized have intrinsic cellular toxicity²⁶. Indeed, all of these materials attempt to chemically damage the virus, but it is a tall order to selectively damage a virus without affecting its host.

An ideal drug should have all the positive properties of virustatic drugs such as broad-spectrum efficacy and low toxicity, and at the same time show a virucidal mechanism. In this paper, we show that it is possible to change the mechanism of inhibition of an antiviral nanoparticle from virustatic to virucidal by engineering its linkers in a way that we hypothesize leads to multivalent binding with the consequent generation of irreversible local distortion, as schematically illustrated in Fig. 1a. Most VALs have binding domains composed of closely packed repeating units; hence they are ideally suited for multivalent binding to their cell receptor. All the known HSPG-mimicking NPs, polymers and dendrimers¹⁵ display short linkers to expose sulfonate groups to the viral ligands, including gold NPs coated with 3-mercaptopethylsulfonate (MES)¹⁶ and heparin. The relative rigidity of the sulfonate linkers should reasonably lead to the binding of only a few of the repeating units that constitute a VAL. Consequently, the resulting binding is weak and reversible^{30,31}. On the other hand, it is known^{30,31} that particles, when binding strongly to a membrane, can lead to significant local distortions. Hence, we replace the short linkers in MES-NPs with long ones, to achieve strong multivalent binding. We show here that strong multivalent binding leads to local distortions and eventually to a global virus deformation, with the consequent irreversible loss of infectivity. We compare MES-coated gold NPs, as well as heparin, with a series of NPs coated with undecanesulfonic acid (MUS)-containing ligands. All NPs show *in vitro* inhibition of many HSPG-dependent viruses, either enveloped (HSV, RSV, lentivirus and dengue virus) or naked (HPV). But whereas the effect of the MES-NPs and heparin is lost upon dilution, all MUS-coated NPs show a clear irreversible effect. As expected the ‘upgrade’ from a virustatic to a virucidal mechanism adds, to all of the positive traits of the former, a strong effect *ex vivo* on human cervicovaginal

histocultures infected by HSV-2 that is absent in the parental virustatic drugs and a strong effect *in vivo* in mice infected with RSV.

Virus and nanoparticles description

To evaluate the inhibitory activity of our NPs we used the following viruses: HSV type 1 (HSV-1), HSV type 2 (HSV-2), pseudoviruses of human papillomavirus type 16 (HPV-16), RSV, vesicular stomatitis virus pseudo-typed lentivirus (LV-VSV-G) and dengue virus. All of the viruses above are HSPG-dependent viruses. We used adenovirus-5 (AD5), a non-HSPG-dependent virus, as a control. To mimic HSPG, we prepared NPs coated with MES and NPs coated with MUS. MES-NPs are reported in the literature and are supposed to be virustatic—that is, the sulfonic acid moieties at the end of their short linkers are effective mimics of HSPG and as a consequence they show good efficacy against a number of HSPG-dependent viruses. The postulated mechanism of virus binding to HSPGs is reversible in nature. To render it irreversible we chose to replace MES with MUS, as this ligand has a long hydrophobic backbone terminating with a sulfonic acid, allowing its terminal group to move with some freedom. Consequently, NPs coated with MUS are ideal for multivalent binding, in this case the binding of multiple sulfonic acids to the HSPG-interacting motifs on the virus surface. Gold NPs coated with MUS ligands were selected, as they are the simplest non-toxic particles that can be synthesized with these ligands. Additional NPs selected in the present study are the particles coated with a 2:1 mixture of MUS and 1-octanethiol (OT), as they are the most biocompatible, soluble, and resistant to protein non-specific adsorption version of MUS-coated gold particles that we have studied^{32–35}. All NPs used are summarized in Table 1, and all synthetic methods and characterizations are presented in the Supplementary Methods and Supplementary Figs 1 to 7.

Viral inhibition

Each virus was pre-incubated with different doses of gold NPs for 1 h at 37 °C and 5% CO₂; then the mixture was added to the cell culture (see Supplementary Methods for virus-specific protocol details, initial viral load, and cell types), and infectivity was tested 24–72 h post-infection. For the GFP-expressing viruses (LV-VSV-G, AD-5 and HPV-16) the infectivity was quantified by flow cytometry, whereas plaque assays were used for wild-type viruses. Table 2 summarizes the results. It is noteworthy that the MUS-functionalized NPs are indeed non-toxic at these concentrations showing favourable selectivity indexes, are able to inhibit infection selectively for HSPG-dependent viruses since no inhibition is observed for AD5, and that all EC₅₀ are in the nanomolar range (see Supplementary Methods for calculations of moles of NP). It is important to underline that the monomeric sulfonated ligand (MUS molecule) was not effective in inhibiting LV-VSV-G (Supplementary Fig. 8). One possible explanation for the lack of inhibition for the MUS molecule could be interactions between various chemical groups on the surface of viruses with the thiols at the end of the ligands. We believe that this explanation is not the correct one, as no inhibitory activity of sodium undec-10-enesulfonate (pre-MUS), a molecule equivalent to MUS but lacking the thiol end-group, was detected against any of the viruses tested.

To further test whether the NPs affect infectivity by mimicking the attachment receptor for HSPG-binding viruses, we performed a series of control experiments. Gold NPs coated with 11-mercaptopundecylphosphoric acid (MUP) ligands (Supplementary Fig. 5) were synthesized, thus creating NPs of similar size, ligand- and charge-density to the MUS-NPs but replacing the sulfonate with phosphonate groups. In contrast to the MUS-NPs, the MUP-NPs showed no inhibitory activity when mixed with pseudo-lentivirus (LV-VSV-G), highlighting the importance of the sulfonic acid group for the activity of the particles. Finally, no inhibitory activity of 15-nm-diameter citrate-coated




Figure 1 | Virucidal activity of MUS:OT-NPs. **a**, Cartoon of the virucidal activity of MUS:OT-NPs compared to MES-NPs. **b**, Heparin, MES-NPs and MUS:OT-NPs viral infectivity curves and virucidal assays. The percentages of infection were calculated by comparing the number of plaques in treated and untreated wells. **c**, Virucidal activity of MUS-coated NPs against HPV-16, RSV, LV-VSV-G (indicated as LV) and DENV-2 viruses. **d**, MUS:OT-NPs inhibition of viral infectivity against HSV-2 versus time (minutes). Results are the mean and s.e.m. of three independent experiments performed in triplicate. *** $p < 0.001$ (two-tailed) in unpaired t test analysis. HSV-2 $t = 0.9788$ $df = 17$, HPV $t = 7.776$ $df = 16$, RSV $t = 44.32$ $df = 6$, LV $t = 5.6$ $df = 2$, DENV $t = 38$, $df = 4$.

gold NPs was detected. In the Supplementary Information we detail experiments aimed at establishing that the particles actually do target the HSPG-seeking VAL.

Virucidal testing

As explained above, other sulfonated materials^{16–19} have also shown similar inhibitory effects as shown for MUS-NPs in Table 2, but these effects have been proven^{10,11} or are assumed³⁶ to be virustatic and hence due to reversible attachment alone. To test whether a different inhibition mechanism was in place for our particles, we first verified the ability of our NPs to inhibit viral attachment, as is known for heparin (Supplementary Fig. 9). Then, we verified

the ability of MUS:OT-NPs, MES-NPs, and heparin to inhibit viral infection. The results are shown in the blue curves in Fig. 1b and summarized in Table 1. In all cases we observed EC_{50} in similar ranges. The inhibition assays were completed by standard toxicity tests. The orange points plotted in Fig. 1b illustrate the results of cell viability studies. In all three cases no toxic effect was observed even at the highest concentrations. We then tested them for irreversible inhibitory activity through virucidal assays. These assays consist of an incubation of the virus and drugs at a concentration corresponding to the EC_{90} for a given amount of time and the subsequent evaluation of the residual infectivity of the virus through serial dilutions of the inoculum. It is known¹⁹

Table 1 | Overview of the nanoparticles used in this study.

Name	Activity	Ligands	Core material	Core size (nm)*
MUS:OT (2:1) [†]	Virucidal		Gold	2.8 ± 0.6
MUS	Virucidal		Gold	2.5 ± 0.7
EG ₂ -OH	Control		Gold	6.2 ± 0.8
MUP	Control		Gold	2.3 ± 1.4
MES	Virustatic		Gold	2.6 ± 0.8
DOS	Virucidal		Iron Oxide	5.0 ± 0.9

*Determined from TEM images and expressed as average diameter ± s.d. [†]Ligand ratio calculated from ¹H NMR analysis after decomposition of the core, see Supplementary Fig. 2.

Table 2 | Inhibitory activity of nanoparticles.

	Virus	EC ₅₀ (μg ml ⁻¹) (95% C.I.)	EC ₅₀ (nM)	CC ₅₀ (μg ml ⁻¹)	SI
MUS:OT-NPs	HSV-1	10.9 (7.65–15.71)	36.3	>300	>27.52
	HSV-2	1.61 (0.81–3.22)	5.3	>300	>186.33
	HPV-16	4.07 (3.17–5.23)	13.6	>300	>73.71
	RSV	9.17 (6.91–12.17)	30.6	>300	>32.71
	LV-VSV-G	10.35 (7.70–13.90)	34.5	>300	>38.98
	AD5	n.a.		>300	n.a.
MUS-NPs	HSV-1	31.30 (26.88–36.45)	104.3	>300	>9.58
	HSV-2	4.10 (1.85–9.06)	13.7	>300	>73.17
	HPV-16	2.2 (0.51–9.49)	7.33	>300	>136.36
	RSV	41.08 (19.60–86.09)	139.3	>300	>7.30
	LV-VSV-G	24.56 (19.87–30.37)	81.9	>300	>12.21
	AD5	n.a.		>300	n.a.
EG ₂ -OH-NPs	HSV-1	n.a.		>300	n.a.
	HSV-2	n.a.		>300	n.a.
	HPV-16	n.a.		>300	n.a.
	RSV	n.a.		>300	n.a.
	LV-VSV-G	n.a.		>300	n.a.
	AD5	n.a.		>300	n.a.
pre-MUS ligand	HSV-1	n.a.		>100	n.a.
	HSV-2	n.a.		>100	n.a.
	HPV-16	n.a.		>100	n.a.
	RSV	n.a.		>100	n.a.
	LV-VSV-G	n.a.		>100	n.a.
	AD5	n.a.		>100	n.a.

EC₅₀: effective concentration 50%. CC₅₀: cytotoxic concentration 50%. SI: selectivity index. n.a. not assessable at tested concentrations.

that if the effect is solely virustatic, the viral infectivity is fully recovered upon dilution, as we show here for heparin and MES gold NPs against HSV-2 (Fig. 1b). As expected in both cases we found these particles to have inhibitory activity in the nanomolar

range¹⁶, but virucidal tests showed recovery of the viral infectivity, indicating a simple virustatic inhibitory mechanism. If irreversible changes are induced in the virus particle, the infectivity is never regained at any dilutions tested, even though the dilution leads to a




Figure 2 | HSV-2 and its association with MUS:OT-NPs. **a–c**, Samples imaged using dry negatively stained TEM (**a**) or unstained cryo-TEM (**b,c**). The scale bars are 100 nm. **d**, Percentage and distribution of NPs (MES or MUS:OT) associated with HSV-2 immediately and after 90 min were determined by analysing between 50 and 100 cryo-TEM images per condition.

final concentration lower than the active dose²². MUS:OT-NPs also showed nanomolar inhibition of HSV-2 infectivity but, in contrast to heparin and MES-NPs, no infectivity was regained upon dilution (Fig. 1b), confirming an irreversible effect (virucidal). In agreement with our hypothesis, all HSPG-binding viruses showed irreversible loss of infectivity when incubated with MUS:OT-NPs, although to differing extents (Fig. 1c).

The HSV-2 virucidal tests were performed also at different time points, as shown in Fig. 1d. Whereas the virustatic effect is immediate, as shown by the dose response curve at time 0 h in Supplementary Fig. 10, the virucidal activity develops over time, with the effect being almost complete after 30 min. Indeed, when viruses and MUS:OT-NPs were mixed and immediately added to cells, the inhibitory potency is reduced as compared to the pre-incubation experiment, confirming the time-dependent virucidal effect (Supplementary Fig. 10).

NPs-induction of irreversible changes in the virus particles

To elucidate the fate of the viruses after NPs binding we performed a series of transmission electron microscopy (TEM) studies on HSV-2 exposed to MUS:OT-NPs and MES-NPs. Dry uranyl acetate negatively stained TEM were complemented by cryo-TEM studies (see Supplementary Discussion for the choice of imaging and its validity). Figure 2a shows negative staining TEM and Fig. 2b,c shows cryo-TEM images of viruses with and without NPs. It is possible to see different types of NP–virus association, categorized as follows: virus with no NPs associated (stage 1); virus with some NPs associated—that is, with particles being mostly isolated (stage 2);

virus with NPs associated with at least one local cluster of NPs (stage 3); and deformed viruses mostly covered with NPs (stage 4). We believe that stage 2 indicates that NPs have associated with the HSPG VALs; as time progresses the VAL attracts more particles leading to stage 3, forming NPs clusters; stage 4 is when the particles are associated with a broken virus or break the virus. Control experiments with particles that had no sulfonic acids show mostly stage 1, and in some rare cases stage 2, that we attribute to stochastic interactions (Supplementary Fig. 11).

The quantification of cryo-TEM images illustrated in Fig. 2d shows that, immediately after mixing HSV-2 with MES-NPs (0.2 mg ml^{-1} , approximate incubation time of 30 s), 75% of the viruses do not show any association with the NPs (stage 1), whereas 25% are associated with the particles (stage 2 and 3). For stage 2 and 3 we observed association primarily at a single point. After 90 min of incubation at 37°C , 5% CO_2 , we find that the fractions of stage 1 versus NP-associated stages remain practically unchanged. The only noticeable difference we found is that the fraction of viruses that was previously in stage 2 now is in stage 3, with 5% showing stage 4 deformed viruses fully coated with NPs. Our interpretation of this data is that in MES-NPs we observe an overall sporadic sizeable interaction with the VAL, leading to a progression from stage 2 to stage 3, while the fraction in stage 4 provides us with a baseline to determine the fraction in our samples of deformed viruses that have lost their capsid integrity and become coated with NPs.

At the same concentration as MES-NPs, the effect of MUS:OT-NPs is markedly different. In this case, all viruses immediately




Figure 3 | Molecular dynamics simulations. **a**, Top view of a small sulfonated MUS:OT-NP (2.4 nm core) selectively binding to HPV capsid L1 protein pentamer, after 25 ns of simulations. Red and yellow spheres show negatively charged terminal sulfonate groups of the MUS-NP. Positively charged HSPG-binding residues of L1 (K278, K356, K361, K54 and K59) are shown in blue. Inset highlights the strong selective coupling between sulfonate groups and HSPG-binding residues (K356, K361, K54 and K59). **b**, Schematic diagram illustrates how strong multi-site binding of MUS-type NPs to HSPG-binding residues can induce irreversible changes in the arrangement of L1 capsid proteins. Scale bars are 1 nm.

associate with particles, showing 50% of stage 2 and 20% of stage 3, and already 30% of the viruses are deformed and fully coated stage 4. After 90 min, images show an evolution of the interaction, as only 13% of the viruses remain in stage 2 and the other 87% are deformed and fully coated stage 4.

In our interpretation, stage 2 and 3 are the imaging of a virustatic effect, as they show NPs attached to viruses, whereas stage 4 is related to the virucidal effect, as it images viruses fully covered with NPs that most probably have lost their structural integrity. When comparing the images for MES-NPs and viruses with those for MUS:OT-NPs and viruses it is noticeable that the immediate association suggests stronger interaction with MUS:OT-NPs, as images lack stage 1. While comparison of the images obtained at 90 min indicates that MUS:OT-NPs induce damage to a fraction of the viruses that is significantly higher than what is observed for MES-NPs (87% versus 5%, respectively). Moreover, image analysis leads to the conclusion that the virucidal action of the MUS:OT-NPs is progressive with time, as established also with virucidal assays (Fig. 1d), because the fraction of viruses imaged in stage 2 and 3 progressively evolves into stage 4. A similar progression can be observed with HPV-16 (Supplementary Fig. 12).

Mechanistic understanding via simulations

To understand how MUS-type NPs can induce irreversible changes upon interaction with HSPG-VALs, we performed atomistic molecular dynamics (MD) simulations of different NPs interacting with the capsid of HPV-16 (Fig. 3). The simulations were performed in physiological solutions, where NPs were placed close to the solvent-exposed HSPG-binding sites (amino acid residues K278, K356, K361, K54 and K59)^{37,38} at the surface of HPV-16 capsid L1 proteins.

The simulation results for MUS:OT-NP 2.4 nm cores, with two types of ligands (MUS and OT) in their ligand shell, 50:50 in composition, are shown in Fig. 3a (Supplementary Movie 1). They demonstrate that selective multivalent binding³⁹ develops between the negative sulfonate groups of MUS:OT-NP and the positive HSPG-binding lysine residues of L1 capsid protein complexes from the HPV-16 capsid. Within 50–80 ns, on average 5–6 local charge interactions form between NP terminal sulfonate groups and L1 HSPG-

binding sites (Supplementary Figs 13 and 14), which are supported by a similar number of non-local coupling contacts between non-polar alkyl chains of NP ligands and L1 proteins. Each of the 5–6 sulfonate groups binds to positively charged amine groups of lysine residues with a relatively large Gibbs free energy of -6 kcal mol^{-1} (ref. 40), totalling in $\Delta G_{\text{bind}} \sim -34 \text{ kcal mol}^{-1}$, while the non-polar ligand chains acquire on average a non-local total binding energy of $-21 \text{ kcal mol}^{-1}$ (see Supplementary Methods for details).

This multivalent binding can induce large stresses and deformations of the L1 complexes. Given the local nature of binding of the sulfonated groups, we can use this binding to estimate the effective force with which the NPs act on the L1 complexes. By considering the increase of binding energy, ΔG_{bind} , during the NP motion, Δx , on the capsid surface, we can get an effective force that drives the NP binding and capsid deformation process forwards, $F \sim -\Delta G_{\text{bind}}/\Delta x$ (Fig. 3b). By combining the above Coulombic energy change of $\Delta G_{\text{bind}} \sim -28 \text{ kcal mol}^{-1}$ and considering, at the beginning of simulations, NP interacting with a lysine, with a distance of 10.4 \AA over which the MUS:OT-NP moves (Supplementary Fig. 15), while acquiring this binding energy, we obtain an effective force of $F \sim 189 \text{ pN}$. This force can deform the L1 complexes and even disturb the relative position of one L1 pentamer with respect to a neighbouring L1 pentamer (Fig. 3b, Supplementary Fig. 16 and Supplementary Movie 2). This disruption of viral capsids by NPs with a multivalent Coulombic binding is analogous to pore formation in neutral membranes by Ca^{2+} ions⁴¹. See Supplementary Discussion for the effect of length on the sulfonated ligand.

Ex vivo activity

To develop an effective antiviral strategy the active substances have to act mainly after infection. We verified whether MUS:OT-NPs were effective also after virus infection of cells. Cells were infected with wild-type HSV-2 at a multiplicity of infection (MOI) of 0.01 plaque-forming units (PFU) per cell for 2 h at 37°C . After removal of the viral inoculum, different doses of MUS:OT-NPs were added to the cell monolayers immediately, or after 2, 4 or 24 h. Cells and supernatants were harvested when the untreated wells exhibited a cytopathic effect of the whole monolayer. The cell-free supernatants




Figure 4 | MUS:OT-NPs activity *ex vivo* and *in vivo*. **a**, NPs activity against HSV-2 infected human cervicovaginal histocultures with pre-incubation of virus and NPs (500 nM) and addition on tissues. **b**, EpiVaginal tissues were treated with MUS:OT-NPs for 18 h and subsequently infected. **c**, EpiVaginal tissues were infected with HSV-2 and after 24 h MUS:OT-NPs were applied to tissues. The percentages of infection were calculated comparing the viral titres in the treated tissues supernatant and in the untreated. Results are the mean and s.e.m. of three independent experiments performed in triplicate. **d**, Groups of 5 BALB/c mice were treated at day 0 with either 50 μ l of PBS or MUS:OT-NPs in PBS (50 μ l at 200 μ g ml⁻¹) and 10 min later where inoculated with RSV-Luc, with the exception of the mock group. Bioluminescence was measured at day 3 post-infection by intranasal injection of D-luciferin. Capture of photon emission was performed using the IVIS system. Luciferase activities were quantified for each mouse using Living Image software. Luciferase activity is expressed as photons per second (p s^{-1}). Results are the mean and s.e.m. of three independent experiments performed with 5 mice per group. *** $p < 0.001$ (two-tailed) in unpaired t test analysis. $t = 8.976$ $df = 8$. **e**, Ventral views of representative mice. The scale indicates the average radiance: the sum of the photons per second from each pixel inside the region of interest/number of pixels ($\text{p s}^{-1} \text{cm}^{-2} \text{sr}^{-1}$).

were then titrated. We determined that MUS:OT-NPs had an EC_{50} of 4.4 μ g ml⁻¹, with complete inhibition at 400 μ g ml⁻¹ and a 3 logs reduction at 80 μ g ml⁻¹ (Supplementary Fig. 17), and a relevant inhibition of infection in all the tested time points. Thus, the NPs can either prevent infection or block an ongoing infectious process, depending on whether they inactivate the virus inoculum or the viral progeny.

To further verify the increased activity of our NPs in a model similar to an *in vivo* infection, we performed antiviral assays in EpiVaginal tissues. These are composed of human-derived ectocervical epithelial cells grown on a collagen-coated membrane to form a multilayered and highly differentiated tissue that is similar to the vaginal mucosa. We used HSV-2 as a challenge due to its specific tropism for the genital mucosa. HSV-2 (10^5 PFU) was pre-incubated with the NPs at 500 nM and then applied to tissues for 2 h at 37 °C. The tissues were washed apically every day and the viral titre was evaluated by titration. The results show a significantly better profile of inhibition of the MUS:OT-NPs compared to the MES-NPs (Fig. 4a). Moreover, we performed experiments in EpiVaginal tissues also pre-treating the tissues for 18 h and subsequently infecting with HSV-2 or infecting the tissue with HSV-2 and treating 24 hours post infection. In both experiments we could observe a significant inhibition with MUS:OT-NPs (Fig. 4b,c) confirming the preventive and therapeutic activity of MUS:OT-NPs observed in cell lines. Moreover, the nanoparticles proved to be non-toxic in MTT and LDH assays conducted on EpiVaginal tissues (Supplementary Fig. 18), demonstrating their biocompatibility with a human mucosa.

In vivo activity

To provide the proof of concept that MUS:OT-NPs could exert inhibitory activity also *in vivo*, we tested them in Balb/c mice

infected with RSV⁴². Three groups of 5 BALB/c mice were treated at day 0 with 50 μ l of PBS, 50 μ l of PBS, or MUS:OT-NPs in PBS (50 μ l at 200 μ g ml⁻¹) in the latter two cases this was followed, 10 min later, by inoculation with RSV-Luc (10^4 PFU). Three days post-infection the luciferase expression in the lungs was analysed as a measure of the extent of infection. As shown in Fig. 4d,e, untreated mice show a clear pulmonary dissemination of RSV infection. By contrast, the luciferase signal from the lungs of the MUS:OT-NPs-treated group was found to be statistically identical to the noise level set by the signal of uninfected mice treated solely with a PBS solution, indicating that MUS:OT-NPs treatment prevented the pulmonary dissemination of the infection.

Moreover, to investigate the biodistribution of MUS:OT-NPs, organ homogenates were subjected to inductively coupled mass spectrometry (ICP-MS) where it was possible to detect presence of gold only in lung homogenates, whereas there was no detectable signal from spleen, liver and brain (Supplementary Fig. 19). Of note, the localization of the MUS:OT-NPs is consistent with their antiviral activity in the lungs, as shown in Fig. 4d,e.

Conclusions

We believe that the approach presented here has a chance to produce medically relevant virucidal drugs to fight viral infections. See Supplementary Discussion for the extension of this work to biodegradable nanoparticles. The results found so far show outstanding virucidal activity over HSV-2 and LS-VSV-G, whereas the activity versus HPV and RSV, although remarkable, should be improved. In any case, it should be stressed that the strategy proposed is intrinsically broad spectrum, allowing the potential prevention and treatment of multiple viral infections with a single drug, a great advantage mostly in virology, where rapid and at

times unexpected infections occur. For example, West Nile, yellow fever, and dengue are growing threats. All these viruses belong to the Flaviviridae family, and are HSPG-binding viruses. Preliminary results with gold NPs show nanomolar virucidal efficacy over dengue 2 (see Fig. 1c and Supplementary Fig. 20). Similarly, the Filoviridae family contains several human pathogens causing haemorrhagic fevers, including Ebola virus, for which drugs are urgently needed. All bind HSPGs as attachment receptors, and are potentially susceptible to the antiviral NPs presented in this study. Overall, what is presented here is a first step towards the development of treatments for many worldwide threatening viral infections. Further in-depth *in vivo* experimentations will be needed to determine whether prophylactic or therapeutic uses of this discovery will be appropriate.

Methods

Methods, including statements of data availability and any associated accession codes and references, are available in the [online version of this paper](#).

Received 22 December 2016; accepted 10 November 2017; published online 18 December 2017

References

- Lozano, R. *et al.* Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)* **380**, 2095–2128 (2012).
- Top 10 causes of death. WHO <http://www.who.int/mediacentre/factsheets/fs310/en> (2017).
- Plotkin, S. A. Vaccines: past, present and future. *Nat. Med.* **11**, S5–S11 (2005).
- De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. *Clin. Microbiol. Rev.* **29**, 695–747 (2016).
- De Clercq, E. Strategies in the design of antiviral drugs. *Nat. Rev. Drug Discov.* **1**, 13–25 (2002).
- Fridland, A., Connelly, M. C. & Robbins, B. L. Cellular factors for resistance against antiretroviral agents. *Antivir. Ther.* **5**, 181–185 (2000).
- Spillmann, D. Heparan sulfate: anchor for viral intruders? *Biochimie* **83**, 811–817 (2001).
- Cagno, V. *et al.* Highly sulfated K5 *Escherichia coli* polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. *Antimicrob. Agents Chemother.* **58**, 4782–4794 (2014).
- Lembo, D. *et al.* Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV. *Eur. J. Pharmaceutics Biopharmaceutics: Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik e.V.* **88**, 275–282 (2014).
- Rusnati, M. *et al.* Sulfated K5 *Escherichia coli* polysaccharide derivatives: a novel class of candidate antiviral microbicides. *Pharmacol. Ther.* **123**, 310–322 (2009).
- Klimytc, E. M., Smith, S. E., Oreste, P., Lembo, D. & Dutch, R. E. Inhibition of human metapneumovirus binding to heparan sulfate blocks infection in human lung cells and airway tissues. *J. Virol.* **90**, 9237–9250 (2016).
- Riblett, A. M. *et al.* A haploid genetic screen identifies heparan sulfate proteoglycans supporting Rift Valley fever virus infection. *J. Virol.* **90**, 1414–1423 (2015).
- Donalisio, M. *et al.* The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice. *Biomaterials* **85**, 40–53 (2016).
- Cagno, V. *et al.* The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses. *Antimicrob. Agents Chemother.* **59**, 5250–5259 (2015).
- Baram-Pinto, D., Shukla, S., Gedanken, A. & Sarid, R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. *Small* **6**, 1044–1050 (2010).
- Bergstrom, D. E. *et al.* Polysulfonates derived from metal thiolate complexes as inhibitors of HIV-1 and various other enveloped viruses *in vitro*. *Antivir. Chem. Chemother.* **13**, 185–195 (2002).
- Bowman, M.-C. *et al.* Inhibition of HIV fusion with multivalent gold nanoparticles. *J. Am. Chem. Soc.* **130**, 6896–6897 (2008).
- Scordi-Bello, I. A. *et al.* Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. *Antimicrob. Agents Chemother.* **49**, 3607–3615 (2005).
- McCormack, S. *et al.* PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. *Lancet* **376**, 1329–1337 (2010).
- Pirrone, V., Wigdahl, B. & Krebs, F. C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. *Antivir. Res.* **90**, 168–182 (2011).
- Van Damme, L. *et al.* Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. *New Engl. J. Med.* **359**, 463–472 (2008).
- Shogan, B., Kruse, L., Mulamba, G. B., Hu, A. & Coen, D. M. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. *J. Virol.* **80**, 4740–4747 (2006).
- Bastian, A. R. *et al.* Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. *ChemMedChem* **6**, 1335–1339 (2011).
- de Souza e Silva, J. M. *et al.* Viral inhibition mechanism mediated by surface-modified silica nanoparticles. *ACS Appl. Mater. Interfaces* **8**, 16564–16572 (2016).
- Bromberg, L. *et al.* Antiviral properties of polymeric aziridine- and biguanide-modified core-shell magnetic nanoparticles. *Langmuir* **28**, 4548–4558 (2012).
- Brogli, J. J. *et al.* Antiviral activity of gold/copper sulfide core/shell nanoparticles against human norovirus virus-like particles. *PLoS ONE* **10**, e0141050 (2015).
- Lara, H. H., Garza-Trevino, E. N., Ixtepan-Turrent, L. & Singh, D. K. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. *J. Nanobiotechnology* **9**, 30 (2011).
- Chen, N. N., Zheng, Y., Yin, J. J., Li, X. J. & Zheng, C. L. Inhibitory effects of silver nanoparticles against adenovirus type 3 *in vitro*. *J. Virol. Methods* **193**, 470–477 (2013).
- Abe, M. *et al.* Effects of several virucidal agents on inactivation of influenza, Newcastle disease, and avian infectious bronchitis viruses in the allantoic fluid of chicken eggs. *Jpn. J. Infect. Dis.* **60**, 342–346 (2007).
- Chaudhuri, A., Battaglia, G. & Golestanian, R. The effect of interactions on the cellular uptake of nanoparticles. *Phys. Biol.* **8**, 046002 (2011).
- Lipowsky, R. & Dobreiner, H. G. Vesicles in contact with nanoparticles and colloids. *Europhys. Lett.* **43**, 219–225 (1998).
- Sabella, S. *et al.* A general mechanism for intracellular toxicity of metal-containing nanoparticles. *Nanoscale* **6**, 7052–7061 (2014).
- Huang, R. X., Carney, R. P., Stellacci, F. & Lau, B. L. T. Colloidal stability of self-assembled mono layer-coated gold nanoparticles: the effects of surface compositional and structural heterogeneity. *Langmuir* **29**, 11560–11566 (2013).
- Huang, R. X., Carney, R. P., Stellacci, F. & Lau, B. L. T. Protein-nanoparticle interactions: the effects of surface compositional and structural heterogeneity are scale dependent. *Nanoscale* **5**, 6928–6935 (2013).
- Huang, R. X., Carney, R. P., Ikuma, K., Stellacci, F. & Lau, B. L. T. Effects of surface compositional and structural heterogeneity on nanoparticle-protein interactions: different protein configurations. *ACS Nano* **8**, 5402–5412 (2014).
- Bathia, S., Cuellar Camacho, L. & Haag, R. Pathogen inhibition by multivalent ligand architectures. *J. Am. Chem. Soc.* **138**, 8654–8666 (2016).
- Dasgupta, J. *et al.* Structural basis of oligosaccharide receptor recognition by human papillomavirus. *J. Biol. Chem.* **286**, 2617–2624 (2011).
- Knappe, M. *et al.* Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. *J. Biol. Chem.* **282**, 27913–27922 (2007).
- Qian, E. Q. *et al.* Atomically precise organomimetic cluster nanomolecules assembled via Perfluoroaryl-Thiol SNAr Chemistry. *Nat. Chem.* **9**, 333–340 (2016).
- Matulis, D. & Lovrien, R. 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. *Biophys. J.* **74**, 422–429 (1998).
- Melcrova, A. *et al.* The complex nature of calcium cation interactions with phospholipid bilayers. *Sci. Rep.* **6**, 38035 (2016).
- Verma, A. *et al.* Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. *Nat. Mater.* **7**, 588–595 (2008).

Acknowledgements

F.S. and his laboratory were supported in part by the Swiss National Science Foundation NRP 64 grant, and by the NCCR on bio-inspired materials. D.L. was supported by a grant from University of Turin (ex 60%). J.H. and J.W. were supported by a research grant from the Ministry of Education, Youth and Sports of the Czech Republic (LK11207). C.T., L.K. and F.S. were supported by the Leenaards Foundation. P.K. was supported by the NSF DMR-1506886 grant. L.V. was supported by startup funding from UTEP. M.G. and R.L. thank the MIMA2 platform for access to the IVIS 200, which was financed by the Ile de France region (SESAME). M.M. thanks R. C. Guerrero-Ferreira for the

tomogram acquisition. P.A. was supported by funding from the European Union Horizon, H2020 Nanofabricating, under grant agreement 646364.

Author contributions

V.C. was responsible for all activities involving HSV2, HPV and RSV under the supervision of D.L. and EpiVaginal experiments under the supervision of C.T. and L.K. P.A. M.D. and C.M. were responsible for all testing with VSV-LV-G under the direction of S.K. P.J.S. was responsible for NP and ligand synthesis. M.M. was responsible for all cryo-TEM. S.T.J. was responsible for iron oxide NP synthesis. M.G. and R.L. were responsible for the *in vivo* experiments, R.W.M. and J.F.E. engineered the RSV-Luc used for *in vivo* experiments. M.V. was responsible for stained TEM imaging of the viruses. J.H. and J.W. conducted all testing with DENV-2. S.S. and Y.H. were responsible for molecular dynamics simulations under the direction of P.K., and L.V. E.R.J. and S.T.J. synthesized MUP-NPs. A.B. synthesized MES-NPs. B.S. synthesized EG2OH-NPs. M.D.

was responsible for HSV-1 and HSV-2 and dose response experiments. F.S. and S.K. first conceived the experiments, F.S. and D.L. developed the interpretation of the experiments. F.S., D.L., V.C. and S.T.J. wrote the paper.

Additional information

Supplementary information is available in the [online version of the paper](#). Reprints and permissions information is available online at www.nature.com/reprints. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to D.L. or F.S.

Competing financial interests

The authors declare no competing financial interests.

Methods

Detailed procedures are provided in the Methods section of the Supplementary Information

Nanoparticles synthesis. MUS:OT and all MUS nanoparticles were synthesized using a slightly modified procedure reported in ref. 43. All MES Au nanoparticles were synthesized following the synthetic procedure reported in ref. 15.

Viral inhibition. Viruses were pre-incubated with nanoparticles for 1 h and then added on cells. Viral infection was evaluated through plaque assay or flow cytometry.

Virucidal assays. Viruses (10^4 – 10^6 PFU) and 100 to 1,000 $\mu\text{g ml}^{-1}$ of MUS:OT-NPs were incubated at different time points at 37 °C and the virucidal effect was investigated with serial dilutions of the mixtures. Viral titres were calculated at dilutions at which the NPs were not effective.

TEM and cryo-TEM. HSV-2 and HPV-PsV (10^5 PFU) were incubated with or without 100 $\mu\text{g ml}^{-1}$ Au-NPs and were adsorbed on carbon- and Formvar-coated grids, negatively stained with 0.5% uranyl acetate, and observed with a CM 10 electron microscope. For cryo-TEM, viruses and NPs were flash-frozen in their native hydrated state on carbon-coated grids and imaged at -175 °C in a FEI Tecnai F20 Cryo 200 kV TEM.

Ex vivo analysis. Epivaginal tissues were purchased from Mattek and cultured as indicated by the manufacturer. The tissues were infected with HSV-2 (10^4 – 10^5 PFU), treated with different NPs (500–1,500 nM), and titrations of supernatants were conducted on Vero cells to evaluate viral replication.

In vivo analysis. Balb/c mice were treated with 200 $\mu\text{g ml}^{-1}$ of MUS:OT-NPs and then infected with RSV-Luc as previously described⁴². Luminescence was measured using the IVIS 200 imaging system (Xenogen Corp.).

Statistics. All results are presented as the mean values and s.e.m. from three independent experiments. The EC_{50} values for inhibition curves were calculated by regression analysis with GraphPad Prism. The selectivity indexes (SI) were calculated by dividing the CC_{50} for the EC_{50} . A unpaired *t*-test analysis was performed for virucidal assays and *in vivo* assays. *t* values and degrees of freedom (df) are indicated in figure legends.

Data availability. Raw data of experiments are available at <https://figshare.com/s/19ed37fbbe0261a00254>

References

43. Rameix-Welti, M.-A. *et al.* Visualizing the replication of respiratory syncytial virus in cells and in living mice. *Nat. Commun.* **5**, 5104 (2014).